Pell Bio-Med Technology Co., Ltd. (TPE:6949)
Taiwan · Delayed Price · Currency is TWD 1,490.00
+135.00 (9.96%)
Aug 26, 2026, 1:30 PM CST
Pell Bio-Med Technology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 28.93 | 31.42 | 19.63 | 18.03 | 17.16 | 13.98 | |
Revenue Growth | 5.45% | 60.07% | 8.86% | 5.11% | 22.75% | - |
Cost of Revenue | 39.35 | 35.82 | 31.96 | 44.17 | 28.41 | 18.35 |
Gross Profit | -10.42 | -4.39 | -12.33 | -26.14 | -11.26 | -4.37 |
Selling, General & Admin | 234.55 | 210.3 | 135.01 | 145.49 | 82.24 | 54.78 |
Research & Development | 252.57 | 252.66 | 266.16 | 239.61 | 142.55 | 136.82 |
Operating Expenses | 487.13 | 462.96 | 401.17 | 385.11 | 224.85 | 191.59 |
Operating Income | -497.54 | -467.35 | -413.5 | -411.25 | -236.11 | -195.96 |
Interest Expense | -1 | -2.05 | -2.26 | -2.56 | -1.36 | -1.52 |
Interest & Investment Income | 16.82 | 11.91 | 15.37 | 7.63 | 2.27 | 0.24 |
Earnings From Equity Investments | 0.01 | -0 | 0.11 | 0.11 | -0 | 0.01 |
Currency Exchange Gain (Loss) | -1.32 | -1.32 | 0.1 | 0.09 | 1.52 | -0.51 |
Other Non Operating Income (Expenses) | -1.71 | 1.01 | 5.82 | 4.86 | 2.41 | 8.97 |
EBT Excluding Unusual Items | -484.75 | -457.8 | -394.36 | -401.11 | -231.27 | -188.76 |
Gain (Loss) on Sale of Investments | 5.13 | 5.13 | -0.62 | - | - | - |
Gain (Loss) on Sale of Assets | - | - | -0.14 | -0.13 | - | -0.2 |
Pretax Income | -479.62 | -452.67 | -395.12 | -401.24 | -231.27 | -188.96 |
Income Tax Expense | - | - | - | 0 | - | - |
Earnings From Continuing Operations | -479.62 | -452.67 | -395.12 | -401.24 | -231.27 | -188.96 |
Minority Interest in Earnings | 43.76 | 28.73 | 5.7 | 2.48 | 1.14 | - |
Net Income | -435.85 | -423.94 | -389.42 | -398.76 | -230.13 | -188.96 |
Net Income to Common | -435.85 | -423.94 | -389.42 | -398.76 | -230.13 | -188.96 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 62 | 59 | 57 | 46 | 39 | 33 |
Shares Outstanding (Diluted) | 62 | 59 | 57 | 46 | 39 | 33 |
Shares Change | 6.45% | 2.77% | 23.33% | 17.94% | 17.87% | - |
EPS (Basic) | -7.03 | -7.23 | -6.83 | -8.62 | -5.87 | -5.68 |
EPS (Diluted) | -7.03 | -7.23 | -6.83 | -8.62 | -5.87 | -5.68 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -627.23 | -507.7 | -523.91 | -196.48 | -167.48 | -122.32 |
Free Cash Flow Per Share | -10.11 | -8.66 | -9.18 | -4.25 | -4.27 | -3.68 |
Gross Margin | -36.01% | -13.97% | -62.79% | -144.96% | -65.61% | -31.27% |
Operating Margin | -1719.94% | -1487.24% | -2106.35% | -2280.52% | -1376.17% | -1402.03% |
Profit Margin | -1506.68% | -1349.09% | -1983.67% | -2211.26% | -1341.32% | -1351.93% |
Free Cash Flow Margin | -2168.24% | -1615.65% | -2668.77% | -1089.53% | -976.14% | -875.12% |
EBITDA | -462.41 | -448.36 | -394.04 | -392.04 | -217.36 | -178.32 |
D&A For EBITDA | 35.13 | 18.99 | 19.46 | 19.21 | 18.75 | 17.65 |
EBIT | -497.54 | -467.35 | -413.5 | -411.25 | -236.11 | -195.96 |